LifeMD, Inc. (LFMD)
NASDAQ: LFMD · Real-Time Price · USD
6.66
+0.03 (0.45%)
Oct 8, 2025, 9:54 AM EDT - Market open
LifeMD Revenue
LifeMD had revenue of $62.22M in the quarter ending June 30, 2025, with 22.81% growth. This brings the company's revenue in the last twelve months to $245.56M, up 37.74% year-over-year. In the year 2024, LifeMD had annual revenue of $212.45M with 39.27% growth.
Revenue (ttm)
$245.56M
Revenue Growth
+37.74%
P/S Ratio
1.16
Revenue / Employee
$799,882
Employees
307
Market Cap
315.80M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 212.45M | 59.91M | 39.27% |
Dec 31, 2023 | 152.55M | 33.51M | 28.15% |
Dec 31, 2022 | 119.03M | 26.16M | 28.16% |
Dec 31, 2021 | 92.88M | 55.58M | 149.04% |
Dec 31, 2020 | 37.29M | 24.83M | 199.10% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
LFMD News
- 1 day ago - LifeMD (LFMD) Sued for Allegedly Misleading Investors on Growth Guidance According to Hagens Berman - GlobeNewsWire
- 1 day ago - LIFEMD DEADLINE REMINDER: Bragar Eagel & Squire, P.C. Urges LifeMD Investors to Contact the Firm Before the October 27th Deadline - GlobeNewsWire
- 2 days ago - LFMD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD - GlobeNewsWire
- 6 days ago - LifeMD (LFMD) Faces Lawsuit Over Alleged Concealment of Cost and Refund Woes in Key Segments, According to Hagens Berman - GlobeNewsWire
- 7 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD - GlobeNewsWire
- 8 days ago - LifeMD to offer Novo's Ozempic at $499 per month to eligible US cash-paying customers - Reuters
- 8 days ago - LifeMD Offers Ozempic® at $499 Per Month through Collaboration with Novo Nordisk - GlobeNewsWire
- 11 days ago - Lawsuit Targets Telehealth Firm LifeMD (LFMD) Over Alleged Misleading Statements According to Hagens Berman - GlobeNewsWire